Ligand Announces Phase IIb Results With DARA Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (the "Company" or "Ligand") announced positive preliminary results from the Phase IIb study for PS433540, the first-in-class Dual Acting Receptor Agonist (DARA) that targets the angiotensin and endothelin receptors. The 261-patient, randomized, double-blind, placebo- and active-controlled study evaluated safety and efficacy at three different doses in subjects with Stage 1 and Stage 2 hypertension over 12 weeks of treatment.
Source: www.medicalnewstoday.comTeaching About Financial Crisis Among Gerontology Meeting's Highlights The Association for Gerontology in Higher Education (AGHE), the educational branch of The Gerontological Society of America, will hold its 35th Annual Meeting and Educational Leadership Conference February 26 - March 1, 2009, at the Crowne Plaza Hotel-Riverwalk in San Antonio, TX. This conference provides a forum for professionals in the field of aging to present their work and share ideas about gerontological and geriatric education and training.
Source: www.medicalnewstoday.comRe-Engineered Hospital Discharge Program Designed To Reduce Rehospitalization Researchers from Boston Medical Center (BMC) and Boston University School of Medicine (BUSM) have designed a process to minimize discharge failures. The Re-Engineered Discharge (RED) program reduces hospital utilization within 30 days of discharge by over 30 percent, by redesigning the discharge workflow process. These findings appear in the February issue of the Annals of Internal Medicine. One in five hospitalizations is complicated by a post-discharge adverse event.
Source: www.medicalnewstoday.comOpinion Leaders In Women's Health To Take The Podium At The 17th Annual Congress On Women's Health Physicians, nurses, allied healthcare providers, and policymakers will gather in Williamsburg, VA on March 27-29, 2009 at the Williamsburg Lodge to learn practical, clinical information on cutting-edge therapeutic protocols, advances in diagnosis and management, and innovative translational research advances that impact patient care from leading experts in women's health. The full program, faculty, accreditation, and registration information is available at
Source: www.medicalnewstoday.comCORLUX(R) Mitigates Weight Gain Associated With Risperdal(R), Expands Corcept Therapeutics (NASDAQ: CORT) announced positive results from a clinical study that tested whether CORLUX mitigates the weight gain associated with Risperdal. The data demonstrated that adding CORLUX to Risperdal treatment in healthy subjects resulted in a statistically significant reduction in weight gain compared to that seen in subjects receiving Risperdal alone.
Source: www.medicalnewstoday.com
# posted by Network @ 9:19 AM
